H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025, passed the House on July 20, 2026.
H.R. 5160 — Stem Cell Therapeutic and Research Reauthorization Act of 2…
What it does
This bill reauthorizes federal funding for two stem cell programs: the C.W. Bill Young Cell Transplantation Program (which collects and stores cord blood for transplants) and the broader Stem Cell Therapeutic and Research Act. It increases funding from $31 million to $33 million annually through 2031, updates rules for managing the national cord blood inventory to prioritize clinical usefulness and genetic diversity, and gives the Secretary of Health and Human Services clearer authority to transfer or dispose of cord blood units that are no longer viable or meet quality standards.
Quorum's transparency scan found no buried provisions in Stem Cell Therapeutic and Research Reauthorization Act of 2025.
What happens next
H.R. 5160 passed the House. It now moves to the other chamber.
Who is behind it
Filed by Chris Smith. Cosponsored by Andrew Garbarino, Brad Finstad, Brian Fitzpatrick and Chellie Pingree.